Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.97 -1.06 (-2.11%)
Streaming Delayed Price Updated: 10:39 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... 
Via Benzinga
P/E Ratio Insights for Sanofi
In the current market session, Sanofi Inc. (NASDAQ:SNY) is trading at $52.60, after a 1.55% decrease. However, over the past month, the stock spiked by 4.32%, and in... 
Via Benzinga
Sanofi Stops Venglustat Development In Rare Genetic Kidney Disorder
Sanofi SA (NASDAQ: SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile of... 
Via Benzinga
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Sanofi SA and GlaxoSmithKline plc have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope to get approved by the end of 2021. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope... 
Via Benzinga
Exposures COVID-19
Sanofi, Walvax COVID-19 Vaccine Phase 3 Trials to Commence in Mexico: Reuters
Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA (NASDAQ: SNY) and China's Walvax... 
Via Benzinga
Exposures COVID-19
Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (... 
Via Benzinga
Sanofi's Amcenestrant Combo Therapy Shows ORR of 34% In Breast Cancer Patients
Sanofi SA (NASDAQ: SNY) revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader. Data will be... 
Via Benzinga
Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients
Eli Lilly and Co (NYSE: LLY) has reported topline data from Phase 3 SURPASS-4 clinical trial evaluating tirzepatide in adults with type 2 diabetes and increased... 
Via Benzinga
Better Buy for 2021: GlaxoSmithKline or Sanofi?
These are two cheap stocks in an overvalued market. 
Via The Motley Fool
GlaxoSmithKline-Medicago's COVID-19 Vaccine Candidate Elicit Strong Immune Response
Interim Phase 2 trial results of GlaxoSmithKline plc (NYSE: GSK) and its collaborating partner Medicago Inc’s COVID-19 vaccine candidate showed... 
Via Benzinga
Exposures COVID-19
Another Tough Day For Markets
The stock market resumed its negativism today mainly linked to fear of inflation and higher interest rates, on the argument that the most dangerous thing to believe is “it's different this time.” 
Via Talk Markets
Sanofi-Regeneron Tout New Data For Dupixent From Pediatric Asthma Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have unveiled detailed results from a Phase 3 trial evaluating Dupixent... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Sanofi-GSK's COVID-19 Vaccine Candidate Reports Success In Mid-Stage Study
Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the... 
Via Benzinga
Exposures Product Safety
15 European Dividend Aristocrats To Diversify Your Portfolio
In general, Dividend Aristocrats are the foundation for the portfolios of most serious dividend growth investors. European Dividend aristocrats are typically blue chip stocks that... 
Via Benzinga
Novavax Reports Positive Data From Animal Trial of Its COVID-19/Flu Combo Shot
Human trials of the combination vaccine are expected to start later this year. 
Via The Motley Fool
Exposures COVID-19
Is Sanofi a Good Buy in 2021?
You might want to add this international blue-chip stock to your portfolio. 
Via The Motley Fool
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... 
Via Benzinga
Could AstraZeneca and Sanofi Win Big in RSV?
The companies have a promising RSV candidate. 
Via The Motley Fool
Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed... 
Via Benzinga
Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy
Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers BioVie (NASDAQ:BIVI) shares increased by 12.96% to $19.78 during Monday's pre-market session. The company's market cap stands at $275.2 million. Ocugen (... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.